Home › Decisions › REPL 2026-04-10

REPL FDA decision — Apr 10, 2026

✕ COMPLETE RESPONSE LETTER

Replimune Group Inc. — RP1 (vusolimogene oderparepvec) and OPDIVO ( · Non-melanoma (NMSC) / Non-small cell lung cancer (.

Run-up into the decision (T-120 → T+5)

Daily close, T-120 (10/24/25) through T+5. Run-up high $10.73 on 12/15/25, low $4.5 on 10/27/25 (T-120 to T-1). FDA decision 4/10/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-04-10

OutcomeCRL

Drug / candidateRP1 (vusolimogene oderparepvec) and OPDIVO (

CompanyReplimune Group Inc.

120-day run-up (T-120→T-1)+26.6%